Merck posts strong 2Q numbers, while building for long term

Drugmaker Merck & Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for cancer and Zepatier for hepatitis C, still posted a big jump in second-quarter profit thanks to slightly higher sales and more cost cutting.